Latest investigations into retatritide peptide reveal promising possibility for treating excess body and non-insulin dependent diabetes mellitus. The peptide, a dual agonist of glucagon-like peptide-1 and GIP, looks to provide enhanced weight loss and glycemic control compared existing treatments